Angiotensin receptor blockers in heart failure

Ostergren, J. and McMurray, J. J.V. (2003) Angiotensin receptor blockers in heart failure. Journal of the Renin-Angiotensin-Aldosterone System, 4(3), pp. 171-175. (PMID:14608522)

Full text not currently available from Enlighten.


Collectively, a series of large, prospective randomised outcome trials has now shown that angiotensin receptor blockers (ARBs) are of clinical value in a broad spectrum of patients with symptomatic heart failure, regardless of background therapy and ventricular function. There is a clear benefit of ARBs in patients unable to tolerate an angiotensin-converting enzyme (ACE) inhibitor and this benefit is of a similar magnitude to that obtained with an ACE inhibitor (ACE-I). Both Val-HeFT and, particularly, CHARM-Added, also show that symptoms, morbidity and mortality are further reduced if an ARB is added to an ACE-I. This benefit is not only statistically significant but clinically important. CHARM-Preserved showed that candesartan can reduce hospital admission for heart failure in patients with preserved systolic function though more definitive outcome data are needed in this group.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Ostergren, J., and McMurray, J. J.V.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Journal of the Renin-Angiotensin-Aldosterone System
Publisher:SAGE Publications
ISSN (Online):1752-8976

University Staff: Request a correction | Enlighten Editors: Update this record